| 5.22 -0.3 (-5.43%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.63  |
1-year : | 8.65 |
| Resists | First : | 6.53 |
Second : | 7.4 |
| Pivot price | 5.87 |
|||
| Supports | First : | 5.11 |
Second : | 4.25 |
| MAs | MA(5) : | 5.49 |
MA(20) : | 6.02 |
| MA(100) : | 5.62  |
MA(250) : | 4.81 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.8 |
D(3) : | 10.9 |
| RSI | RSI(14): 38.3 |
|||
| 52-week | High : | 12.69 | Low : | 3.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MOLN ] has closed above bottom band by 12.9%. Bollinger Bands are 18.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.34 - 5.36 | 5.36 - 5.39 |
| Low: | 5.04 - 5.07 | 5.07 - 5.1 |
| Close: | 5.16 - 5.21 | 5.21 - 5.26 |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Wed, 11 Sep 2024
Molecular Partners (NASDAQ:MOLN) Shares Down 0.3% - MarketBeat
Tue, 10 Sep 2024
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate - Simply Wall St
Mon, 26 Aug 2024
Molecular Partners Reports H1 2024 Corporate Highlights and Financials - StockTitan
Tue, 20 Aug 2024
Investors in Molecular Partners (VTX:MOLN) have unfortunately lost 69% over the last three years - Yahoo Finance
Tue, 06 Aug 2024
Molecular Partners AG's (VTX:MOLN) market cap dropped CHF20m last week; Retail investors bore the brunt - Simply Wall St
Mon, 17 Jun 2024
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 1.732e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 66 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.105e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 30 % |
| Return on Equity (ttm) | -19.4 % |
| Qtrly Rev. Growth | 7.86e+006 % |
| Gross Profit (p.s.) | 421.07 |
| Sales Per Share | -49.05 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 0.72 |
| Dividend | 0 |
| Forward Dividend | 32680 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|